picropodophyllin has been researched along with Multiple Myeloma in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Axelson, M; Bieghs, L; De Bruyne, E; Fostier, K; Jernberg-Wiklund, H; Johnsen, HE; Larsson, O; Lub, S; Maes, K; Menu, E; Nyegaard, M; Overgaard, MT; Schots, R; Van Valckenborgh, E; Vanderkerken, K | 1 |
| Agarwal, P; Atadja, P; Axelson, M; De Bruyne, E; Fristedt, C; Jernberg-Wiklund, H; Larsson, O; Lemaire, M; Menu, E; Österborg, A; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K | 1 |
| Asosingh, K; Axelson, M; De Raeve, H; Girnita, L; Jernberg-Wiklund, H; Larsson, O; Menu, E; Nilsson, K; Stromberg, T; Van Camp, B; Vanderkerken, K | 1 |
| Axelson, M; Carlson, K; Dimberg, LY; Ekman, S; Girnita, L; Hellman, U; Jernberg-Wiklund, H; Larsson, O; Lennartsson, J; Nilsson, K; Osterborg, A; Strömberg, T; Vanderkerken, K | 1 |
| Jernberg-Wiklund, H; Nilsson, K | 1 |
| Axelson, M; Coulton, L; Croucher, P; De Leenheer, E; De Raeve, H; Gallagher, O; Jernberg-Wiklund, H; Larsson, O; Menu, E; Nilsson, K; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K | 1 |
1 review(s) available for picropodophyllin and Multiple Myeloma
| Article | Year |
|---|---|
Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dexamethasone; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor I; Mice; Mice, Inbred BALB C; Mice, SCID; Models, Molecular; Multiple Myeloma; Neoplasm Proteins; Podophyllotoxin; Protein Conformation; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; Sirolimus | 2007 |
5 other study(ies) available for picropodophyllin and Multiple Myeloma
| Article | Year |
|---|---|
The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomimetic Materials; Biphenyl Compounds; Cell Line, Tumor; Drug Synergism; Humans; Mice; Mice, Inbred C57BL; Multiple Myeloma; Nitrophenols; Piperazines; Podophyllotoxin; Receptor, IGF Type 1; Sulfonamides | 2014 |
The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.
Topics: Animals; Apoptosis; Caspase 8; Cell Adhesion; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Gene Expression Profiling; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mice; Mice, Inbred C57BL; Multiple Myeloma; Panobinostat; Podophyllotoxin; Receptor, IGF Type 1; Transcriptome; Tumor Cells, Cultured | 2012 |
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.
Topics: Animals; Bone Marrow; Cell Proliferation; Disease Models, Animal; Enzyme Activation; In Vitro Techniques; Insulin-Like Growth Factor I; Mice; Mice, Inbred C57BL; Microcirculation; Mitogen-Activated Protein Kinase 1; Multiple Myeloma; Neovascularization, Pathologic; Paraproteins; Phosphorylation; Podophyllotoxin; Receptor, IGF Type 1; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2006 |
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells.
Topics: Apoptosis; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Enzyme Activation; G2 Phase; Humans; Inhibitor of Apoptosis Proteins; Insulin; Insulin-Like Growth Factor I; Interleukin-6; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinase 1; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phosphorylation; Podophyllotoxin; Proto-Oncogene Proteins c-bcl-2; Receptor, IGF Type 1; Receptor, Insulin; Survivin; Tumor Cells, Cultured | 2006 |
Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bone Neoplasms; Disease Models, Animal; Kaplan-Meier Estimate; Mice; Multiple Myeloma; Neovascularization, Pathologic; Podophyllotoxin; Receptor, IGF Type 1 | 2007 |